Äèñêóññèîííûé Êëóá

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Íåâðîëîãèÿ è íåéðîõèðóðãèÿ

Íåâðîëîãèÿ è íåéðîõèðóðãèÿ Ôîðóìû: Ôîðóì äëÿ îáùåíèÿ âðà÷åé íåâðîëîãîâ è íåéðîõèðóðãîâ, Ìàíóàëüíàÿ òåðàïèÿ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 18.09.2004, 15:12
katerpiller74 katerpiller74 âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 18.09.2004
Ãîðîä: Òóëà
Ñîîáùåíèé: 10
katerpiller74 ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
ïîëèóðèÿ ïðè Î×ÌÒ

Óâàæàåìûå êîëëåãè, ïðîÿâëÿþ íåäîïîíèìàíèå, íåñïîñáåí ðàçðåøèòü ñîáñòâåííûìè ñèëàìè- ó áîëüíîãî îòêðûòàÿ ×ÌÒ, 9 ñóòêè, íàðàñòàåò ïîëëèóðèÿ-ïåðâîíà÷àëüíî ñ íîðìàëüíûìè ïîêàçàòåëÿìè íàòðèÿ è êàëèÿ,íîðìàëüíîé îñìîëÿðíîñòüþ, íà 11-12 äåíü ñíèæàåòñÿ óðîâåíü íàòðèÿ äî êðèòè÷åñêèõ öèôð, ïëîòíîñòü ìî÷è 1010-1015, ãëèêåìèÿ 6,5-4,5, ââåäåíèå 4,5% ðàñòâîðà íàòðèÿ õëîðèäà íå ïðèâîäèò ê ïîâûøåíèþ óðîâíÿ â ñûâîðîòêå è îñìîëÿðíîñòè, ñîõðàíÿåòñÿ íîðìàëüíàÿ ïëîòíîñòü ìî÷è.Êîëëåãèàëüíî ðåøåíî ââåñòè ýêçîãåííî ìèíåðàëîêîðòèêîîîèäû-ñ íåáîëüøèì ïîëîæèòåëüíûì ýôôåêòîì. Ïðîøó ïîìî÷ü â ðàçúÿñíåíèè ñèòóàöèè, îòïðàâèòü ê ïåðâîèñòî÷íèêàì.
Ñ óâàæåíèåì Êóäðÿâöåâ Àíòîí.
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 18.09.2004, 23:17
Àâàòàð äëÿ thorn
thorn thorn âíå ôîðóìà ÂÐÀ×
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 10.04.2003
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 782
Ïîáëàãîäàðèëè 15 ðàç(à) çà 15 ñîîáùåíèé
thorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äàííûõ íåäîñòàòî÷íî. Åñëè åñòü âîçìîæíîñòü, óêàæèòå îñìîëÿðíîñòü ïëàçìû è ìî÷è, íàòðèé â ïëàçìå è ìî÷å, êîëè÷åñòâî ìî÷è â ñóòêè è ÖÂÄ. Âîçìîæíî, ÷òî ó Âàøåãî ïàöèåíòà cerebral salt wasting syndrome (CSWS), îäíàêî íåëüçÿ òàêæå èñêëþ÷èòü è SIADH (ñèíäðîì íåàäåêâàòíîé ñåêðåöèè ÀÄÃ). Íåïëîõîé îáçîð â òåìó çäåñü. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 19.09.2004, 13:01
Mikhail Mikhail âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 02.12.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 3,214
Ñêàçàë(à) ñïàñèáî: 3
Ïîáëàãîäàðèëè 121 ðàç(à) çà 119 ñîîáùåíèé
Mikhail ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMikhail ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMikhail ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMikhail ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMikhail ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMikhail ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMikhail ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMikhail ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMikhail ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMikhail ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMikhail ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïîëèóðèÿ - ïàòîãíîìîíè÷íûé ïðèçíàê ãóáîêîé êîìû ñâÿçàííîé ñ âûñîêèì Â×Ä è ñìåðòè ìîçãà. Ñâÿçàíà ñ ïîðàæåíèåì ãèïîòàëàìî-ãèïîôèçàðíîé ñèñòåìû.
Êàêîé ñ÷¸ò ïî ØÊÃ?
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 19.09.2004, 14:10
Àâàòàð äëÿ Alon
Alon Alon âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 17.08.2004
Ãîðîä: Israel
Ñîîáùåíèé: 719
Alon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò katerpiller74
... íà 11-12 äåíü ñíèæàåòñÿ óðîâåíü íàòðèÿ äî êðèòè÷åñêèõ öèôð...
Ïðîøó ïîìî÷ü â ðàçúÿñíåíèè ñèòóàöèè, îòïðàâèòü ê ïåðâîèñòî÷íèêàì.
Ñ óâàæåíèåì Êóäðÿâöåâ Àíòîí.
----------------------------------------------------------------
D/Diagnosis of Hypotonic Hyponatremia

Hypovolemic
TBW-
TBNa--
» Urine Sodium: >20 mmol/L
» Diagnosis: Renal Losses:
Diuretic Therapy
Osmotic Diuresis
Salt-Wasting Nephropathy
Adrenal Insufficiency (Mineralocorticoid def)
Proximal Renal Tubular Acidosis
Metabolic Alkalosis
Pseudohypoaldosteronism
Cerebral Salt-Wasting



• Hypovolemic
TBW-
TBNa--
» Urine Sodium: <20 mmol/L
» Diagnosis: Extrarenal Losses:
Gastrointestinal
Sweat
Third Space (Burns, Ascites, Effusions)

• Euvolemic
TBW+
TBNa+-
» Urine Sodium: >20 mmol/L
» Diagnosis: Excess ADH (SIADH*, Drugs, Pain)
Water Intoxication (IV Therapy, Psychogenic Water Drinking, Tap Water Enema)
Reset Osmostat
Glucocorticoid Deficiency
Hypothyroidism

• Hypervolemic
TBW++
TBNa+
» Urine Sodium: <20 mmol/L
» Diagnosis: Edematous Congestive Heart Failure
Cirrhosis
Nephrotic Syndrome


• Hypervolemic
TBW++
TBNa+
» Urine Sodium: >20 mmol/L
» Diagnosis: Renal Failure (Acute or Chronic)
TBW= Total body water; TBNa= Total body sodium
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 21.09.2004, 17:50
katerpiller74 katerpiller74 âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 18.09.2004
Ãîðîä: Òóëà
Ñîîáùåíèé: 10
katerpiller74 ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
Áîëüøîå ñïàñèáî, ÷òî óäåëèëè ìíå âðåìÿ. Îñìîëÿðíîñòü ïëàçìû ñîõðàíÿëàñü íèçêîé, ïàðàëëåëüíî óðîâíþ íàòðèÿ- ìåíåå 240 ìîñìîëü\ë, ïðè íàòðèè ïëàçìû 118-120 ìêìîëü\ë, ïîñëå íà÷àëà ââåäåíèÿ ìèíåðàëîêîðòèêîèèäîâ â òå÷åíèè 3-4 äíåé ïðèøëî â íîðìó, áåç óñèëèé. ÖÂÄ íà ïåðèîä ïîëëèóðèè -îòðèöàòåëîíîå-1-2 ñì Í2Î, ìî÷è áîîëåå 5-6 ëèòðîâ â ñóòêè.Ïîâòîðþñü-íà ìèíåðàëîêîðòèêîèäàõ -ïðèøëî ê óäîâëåòâîðèòåëüíûì âåëè÷èíàì. Îãðîìíîå ñïàñèáî çà âííèìàíèå è ññûëêó.
Ñ óâàæåíèåì Êóäðÿâöåâ Àíòîí.
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 21.09.2004, 17:55
katerpiller74 katerpiller74 âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 18.09.2004
Ãîðîä: Òóëà
Ñîîáùåíèé: 10
katerpiller74 ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
Îãðîìíîå ñïàñèáî çà âíèìàíèå è ïîíèìàíèå. Ïîñòóïàë íà 9 áàëëîâ. Íà ìîìåíò ðàçâèòèÿ ïîëèóðèè 11-12 áàëëîâ. Ïîñëå íîðìàëèçàöèè âîäíî-ýëåêòðîëèòíîãî áàëàíñà-ïðåæäå âñåãî óðîâíÿ íàòðèÿ â ïëàçìå (÷åòâåðòûå ñóòêè ïðèìåíåíèÿ ìèíåðàëîêîðòèêîèäîâ) óìåðåííîå îãëóøåíèå íà13-14 áàëëîâ, ñ âûðàæåíííîé ðå÷åâîé ïðîäóêöèåé, äèñëàëèåé è êîïðîëàëèåé.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 22.09.2004, 10:07
Àâàòàð äëÿ thorn
thorn thorn âíå ôîðóìà ÂÐÀ×
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 10.04.2003
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 782
Ïîáëàãîäàðèëè 15 ðàç(à) çà 15 ñîîáùåíèé
thorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò katerpiller74
Îñìîëÿðíîñòü ïëàçìû ñîõðàíÿëàñü íèçêîé, ïàðàëëåëüíî óðîâíþ íàòðèÿ- ìåíåå 240 ìîñìîëü\ë, ïðè íàòðèè ïëàçìû 118-120 ìêìîëü\ë, ïîñëå íà÷àëà ââåäåíèÿ ìèíåðàëîêîðòèêîèèäîâ â òå÷åíèè 3-4 äíåé ïðèøëî â íîðìó, áåç óñèëèé. ÖÂÄ íà ïåðèîä ïîëëèóðèè -îòðèöàòåëîíîå-1-2 ñì Í2Î, ìî÷è áîîëåå 5-6 ëèòðîâ â ñóòêè.
Ïîõîæå, ýòî cerebral salt wasting syndrome. Ñðîêè íà÷àëà, ãèïîíàòðèåìèÿ, ãèïîîñìèÿ, ïîëèóðèÿ è ñíèæåíèå ýôôåêòèâíîãî ÎÖÊ. Íåïîíÿòåí ýôôåêò ìèíåðàëîêîðòèêîèäîâ.  ïðèíöèïå, äîñòàòî÷íî ïðîñòî "äîëèâàòü" ôèç. ðàñòâîðîì. À ñêîëüêî ñóòîê ïðîäîëæàëñÿ ïåðèîä ïîëèóðèè? Ìîæåò ïðîñòî ñîâïàäåíèå?
Åùå îäèí îáçîð, áîëåå ïîäðîáíûé. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
Mikhail îäîáðèë(à): Ñïàñèáî çà èíòåðåñíóþ ññûëêó
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 22.09.2004, 11:04
Àâàòàð äëÿ Alon
Alon Alon âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 17.08.2004
Ãîðîä: Israel
Ñîîáùåíèé: 719
Alon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlon ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò thorn
Íåïîíÿòåí ýôôåêò ìèíåðàëîêîðòèêîèäîâ. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
" The mineralocorticoid fludrocortisone acetate directly acts on the renal tubule to enhance sodium reabsorption. Prompt resolution of hyponatremia was reported after administration of fludrocortisone in three elderly patients with CSW after head injury." - Mark R. Harrigan, Cerebral Salt Wasting Syndrome, Critical Care Clinics,Volume 17,Number 1,January 2001 (cì. ôàéë)

Êîììåíòàðèè ê ñîîáùåíèþ:
Mikhail îäîáðèë(à): Ñïàñèáî çà èíòåðåñíóþ ññûëêó
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 22.09.2004, 18:48
Àâàòàð äëÿ thorn
thorn thorn âíå ôîðóìà ÂÐÀ×
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 10.04.2003
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 782
Ïîáëàãîäàðèëè 15 ðàç(à) çà 15 ñîîáùåíèé
thorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåthorn ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Èíòåðåñíî... Ñïàñèáî çà èíôó. Ó íàñ äîñòóïåí ïîëüñêèé ôëóäðîêîðòèçîí (êîðòèíåôô) ïî 0.1 ìã â òàáëåòêå.
Åñëè ìèíåðàëîêîðòèêîèäû ýôôåêòèâíû, òî ìîæåò è ãëþêîêîðòèêîèäû òîæå? Âî âñÿêîì ñëó÷àå ïî ãîðÿ÷èì ñëåäàì:


Moro N, Katayama Y, Kojima J, Mori T, Kawamata T. Prophylactic management of excessive natriuresis with hydrocortisone for efficient hypervolemic therapy after subarachnoid hemorrhage. Stroke. 2003 Dec;34(12):2807-11.

BACKGROUND AND PURPOSE: Hyponatremia caused by excessive natriuresis is common in patients with aneurysmal subarachnoid hemorrhage (SAH). Natriuresis decreases the total blood volume through osmotic diuresis and increases the risk of symptomatic cerebral vasospasm. In such patients, hypervolemic therapy is difficult to achieve without causing hyponatremia because sodium replacement provokes further natriuresis and osmotic diuresis. We examined the effects of hydrocortisone, which promotes sodium retention, in patients with SAH. METHODS: Twenty-eight SAH patients were randomized into 2 groups after direct surgery: group 1 patients without hydrocortisone treatment (n=14) and group 2 patients with hydrocortisone treatment (1200 mg/d for 10 days; n=14). Both groups underwent hypervolemic therapy by aggressive sodium and water replacement. The goal of the hypervolemic therapy was to maintain the serum sodium level >140 mEq/L and the central venous pressure (CVP) within 8 to 12 cm H2O. RESULTS: Group 2 demonstrated a lower sodium excretion (P<0.05) and higher serum sodium level (P<0.05) compared with group 1. Hyponatremia developed in 6 patients (43%) in group 1 and 0 patients in group 2 (P<0.05). Group 2 also demonstrated a lower urine volume, lower infusion volume (P<0.05) required for hypervolemic therapy, and higher CVP (P<0.05). Failure to maintain CVP was observed in 12 patients (86%) in group 1 and 3 patients (21%) in group 2 (P<0.05). Hydrocortisone caused no serious side effects. CONCLUSIONS: Hydrocortisone clearly attenuates excessive natriuresis. Prophylactic hydrocortisone administration appears to have a therapeutic value in inducing hypervolemia efficiently after SAH.
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 27.09.2004, 09:57
katerpiller74 katerpiller74 âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 18.09.2004
Ãîðîä: Òóëà
Ñîîáùåíèé: 10
katerpiller74 ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
Î÷åíü áëàãîäàðåí çà ïîìîùü è ïîäðîáíûå ññûëêè. Ïîëëèóðèÿ ïðîäîëæàëàñü â òå÷åíèè 10 äíåé, ïðè ýòîì íà ôîíå èíôóçèîííîé òåðàïèè îáùåìîçãîâàÿ ñèìïòîìàòèêà ðåãðåññèðîâàëà.Òîæå ïðèìåíÿëè êîðòèíåô.
Ñ óâàæåíèåì Êóäðÿâöåâ Àíòîí.
Îòâåòèòü ñ öèòèðîâàíèåì
  #11  
Ñòàðûé 27.09.2004, 10:03
katerpiller74 katerpiller74 âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 18.09.2004
Ãîðîä: Òóëà
Ñîîáùåíèé: 10
katerpiller74 ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò thorn
Èíòåðåñíî... Ñïàñèáî çà èíôó. Ó íàñ äîñòóïåí ïîëüñêèé ôëóäðîêîðòèçîí (êîðòèíåôô) ïî 0.1 ìã â òàáëåòêå.
Åñëè ìèíåðàëîêîðòèêîèäû ýôôåêòèâíû, òî ìîæåò è ãëþêîêîðòèêîèäû òîæå? Âî âñÿêîì ñëó÷àå ïî ãîðÿ÷èì ñëåäàì:


Moro N, Katayama Y, Kojima J, Mori T, Kawamata T. Prophylactic management of excessive natriuresis with hydrocortisone for efficient hypervolemic therapy after subarachnoid hemorrhage. Stroke. 2003 Dec;34(12):2807-11.

BACKGROUND AND PURPOSE: Hyponatremia caused by excessive natriuresis is common in patients with aneurysmal subarachnoid hemorrhage (SAH). Natriuresis decreases the total blood volume through osmotic diuresis and increases the risk of symptomatic cerebral vasospasm. In such patients, hypervolemic therapy is difficult to achieve without causing hyponatremia because sodium replacement provokes further natriuresis and osmotic diuresis. We examined the effects of hydrocortisone, which promotes sodium retention, in patients with SAH. METHODS: Twenty-eight SAH patients were randomized into 2 groups after direct surgery: group 1 patients without hydrocortisone treatment (n=14) and group 2 patients with hydrocortisone treatment (1200 mg/d for 10 days; n=14). Both groups underwent hypervolemic therapy by aggressive sodium and water replacement. The goal of the hypervolemic therapy was to maintain the serum sodium level >140 mEq/L and the central venous pressure (CVP) within 8 to 12 cm H2O. RESULTS: Group 2 demonstrated a lower sodium excretion (P<0.05) and higher serum sodium level (P<0.05) compared with group 1. Hyponatremia developed in 6 patients (43%) in group 1 and 0 patients in group 2 (P<0.05). Group 2 also demonstrated a lower urine volume, lower infusion volume (P<0.05) required for hypervolemic therapy, and higher CVP (P<0.05). Failure to maintain CVP was observed in 12 patients (86%) in group 1 and 3 patients (21%) in group 2 (P<0.05). Hydrocortisone caused no serious side effects. CONCLUSIONS: Hydrocortisone clearly attenuates excessive natriuresis. Prophylactic hydrocortisone administration appears to have a therapeutic value in inducing hypervolemia efficiently after SAH.
Ìû òîæå ïðèìåíÿëè êîðòèíåô, -â òå÷åíèè 5 äíåé, ïîääåðæèâàþùàÿ òåðàïèÿ íå ïðîâîäèëàñü, ïàðåíòåðàëüíî, îòìåíåí áûë ñðàçó.
Ñ óâàæåíèåì Êóäðÿâöåâ Àíòîí

Êîììåíòàðèè ê ñîîáùåíèþ:
Alexei îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 02:43.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.